AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29404725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg + MTX
Number of subjects: 9753
Study 29404725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg + MTX
Number of subjects: 9753
Study 29404725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg + MTX
Number of subjects: 9753
Study 29404725 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Number of subjects: 9753
Study 29404725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg
Number of subjects: 9753
Study 29404725 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MTX
Number of subjects: 9753
Study 29404725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg + MTX, Sirukumab 100 mg + MTX, Sarilumab 200 mg + MTX
Number of subjects: 9753
Study 28490337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 115
Study 28490337 — intervention group
Group type: COMPARATOR
Intervention: Conventional antidiabetic treatment
Number of subjects: 115
Study 28490337 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin and Conventional treatment
Number of subjects: 115
Study 25642600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical dilatation
Number of subjects: 199
Study 25642600 — intervention group
Group type: COMPARATOR
Intervention: Non-dilated group
Number of subjects: 199
Study 23343676 — intervention group
Group type: COMPARATOR
Intervention: EAA
Number of subjects: 21
Study 23343676 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA+ALA
Number of subjects: 21
Study 23343676 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA+CHO
Number of subjects: 21
Study 20214441 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-metronidazole combination and scaling and root planing
Number of subjects: 28
Study 20214441 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 28
Study 19016206 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL pattern scanning laser (group 1)
Number of subjects: 33
Study 19016206 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lesion technique (group 2)
Number of subjects: 33
Study 19016206 — intervention group
Group type: COMPARATOR
Intervention: Conventional single spot laser coagulation (control)
Number of subjects: 33
Study 16388496 — intervention group
Group type: EXPERIMENTAL
Intervention: Having an HIV-positive spouse
Number of subjects: 995
Study 16388496 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive for herpes simplex virus type 2 (HSV-2)
Number of subjects: 995
Study 16388496 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-2-positive at baseline
Number of subjects: 995
Study 16388496 — intervention group
Group type: EXPERIMENTAL
Intervention: Living elsewhere
Number of subjects: 995
Study 16388496 — intervention group
Group type: EXPERIMENTAL
Intervention: Never having given birth
Number of subjects: 995
Study 16388496 — intervention group
Group type: COMPARATOR
Intervention: History of injections or STIs
Number of subjects: 995
Study 14647223 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g recombinant human lactoferrin
Number of subjects: 15
Study 14647223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10914845 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-rigid orthoses worn in supportive shoes
Number of subjects: 28
Study 10914845 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft orthoses worn in supportive shoes
Number of subjects: 28
Study 10914845 — intervention group
Group type: COMPARATOR
Intervention: Supportive shoes worn alone
Number of subjects: 28
Study 9051165 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) at Zusanli (St. 36), Sanyinjiao (Sp. 6), Hegu (L.I.4), and Neiguan (P.6) points
Number of subjects: 0
Study 9051165 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (1 mg)
Number of subjects: 0
Study 9051165 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (1 microgram/1 microliter) microinjected into periaqueductal gray (PAG)
Number of subjects: 0
Study 9051165 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) at Zusanli (St. 36) after naloxone microinjection into PAG
Number of subjects: 0
Study 1478801 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice operation
Number of subjects: 142
Study 1478801 — intervention group
Group type: COMPARATOR
Intervention: Bassini-Kirschner operation
Number of subjects: 142
Study 6150365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine plus pyrimethamine-sulfadoxine ('Fansidar')
Number of subjects: 80
Study 6150365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine plus qinghaosu
Number of subjects: 80
Study 6150365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine, fansidar, and qinghaosu
Number of subjects: 80
Study 6150365 — intervention group
Group type: EXPERIMENTAL
Intervention: Qinghaosu alone
Number of subjects: 80
Study 31267698 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA-positive participants (GADA ≥ 5 U/mL)
Number of subjects: 95
Study 31267698 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA-negative participants (GADA < 5 U/mL)
Number of subjects: 95
Study 31267698 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with DRB1*09:01
Number of subjects: 95
Study 31267698 — intervention group
Group type: COMPARATOR
Intervention: Acute-onset type 1 diabetes participants
Number of subjects: 95
Study 28986245 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM2ACT smartphone application
Number of subjects: 50
Study 28986245 — intervention group
Group type: COMPARATOR
Intervention: Self-guided asthma control condition
Number of subjects: 50
Study 27326429 — intervention group
Group type: EXPERIMENTAL
Intervention: SPRINT patients
Number of subjects: 442
Study 27326429 — intervention group
Group type: COMPARATOR
Intervention: non-SPRINT patients
Number of subjects: 442
Study 24557989 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line pre-dilution haemofiltration (HF), 36 patients
Number of subjects: 146
Study 24557989 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line pre-dilution haemodiafiltration (HDF), 40 patients
Number of subjects: 146
Study 24557989 — intervention group
Group type: COMPARATOR
Intervention: Low-flux haemodialysis (HD), 70 patients
Number of subjects: 146
Study 22939457 — intervention group
Group type: EXPERIMENTAL
Intervention: web-based multimedia consent
Number of subjects: 35
Study 22939457 — intervention group
Group type: COMPARATOR
Intervention: routine consent
Number of subjects: 35
Study 20357008 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60
Study 20357008 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60
Study 20357008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study 17336171 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal screening and treatment of mothers with penicillin
Number of subjects: 0
Study 17336171 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care decentralized screening and treatment
Number of subjects: 0
Study 17336171 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative approaches to controlling congenital syphilis
Number of subjects: 0
Study 17336171 — intervention group
Group type: EXPERIMENTAL
Intervention: International health agencies support
Number of subjects: 0
Study 16303217 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg at 0, 1 months (Group A)
Number of subjects: 990
Study 16303217 — intervention group
Group type: COMPARATOR
Intervention: 10 microg at 0, 1 and 2 months (Group B - Control)
Number of subjects: 990
Study 16303217 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg at 0, 1 and 2 months (Group C)
Number of subjects: 990
Study 12215911 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg bid
Number of subjects: 60
Study 12215911 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 microg bid
Number of subjects: 60
Study 10205213 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% GTN three times daily
Number of subjects: 70
Study 10205213 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating dose GTN starting at 0.2% with weekly 0.1% increments to a maximum of 0.6%
Number of subjects: 70
Study 10205213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 8555514 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient questionnaire (mailed back)
Number of subjects: 400
Study 8555514 — intervention group
Group type: COMPARATOR
Intervention: Surgeon follow‐up card
Number of subjects: 400
Study 8555514 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient questionnaire (telephoned by an infection control practitioner)
Number of subjects: 400
Study 2378773 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil
Number of subjects: 29
Study 2378773 — intervention group
Group type: COMPARATOR
Intervention: fentanyl
Number of subjects: 29
Study 503379 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 75
Study 503379 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 75
Study 31663855 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended CBT (10 weekly face-to-face sessions and 9 web-based sessions)
Number of subjects: 102
Study 31663855 — intervention group
Group type: COMPARATOR
Intervention: Standard CBT (15 to 20 weekly face-to-face sessions)
Number of subjects: 102
Study 31663855 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended CBT
Number of subjects: 102
Study 28556432 — intervention group
Group type: EXPERIMENTAL
Intervention: One-piece dental implants (S1)
Number of subjects: 60
Study 28556432 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-piece dental implants (S2)
Number of subjects: 60
Study 25981812 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 58
Study 25981812 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy with mediastinal lymph node dissection or sampling (surgery)
Number of subjects: 58
Study 23649498 — intervention group
Group type: EXPERIMENTAL
Intervention: Montgomery Safe‐T‐Tube removed 3 to 15 days after insertion (group A)
Number of subjects: 16
Study 23649498 — intervention group
Group type: COMPARATOR
Intervention: Montgomery Safe‐T‐Tube removed at least 90 days after insertion (group B)
Number of subjects: 16
Study 21411512 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant methionyl human leptin (30 mg/day)
Number of subjects: 100
Study 21411512 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose recombinant methionyl human leptin (80 mg/day)
Number of subjects: 100
Study 21411512 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study 18923838 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheopheresis (two treatments, each lasting about 2 hours, within 3 days)
Number of subjects: 240
Study 18923838 — intervention group
Group type: COMPARATOR
Intervention: Control group (i.v. corticosteroids: methylprednisolon 250 mg for 3 days and tapering to zero, or i.v. hemodilution: 500 mL 6% hydroxyethyl starch plus 600 mg pentoxifylline per day for 10 days)
Number of subjects: 240
Study 18923838 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheopheresis
Number of subjects: 240
Study 16583215 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DTPA contrast agent during bolus administration
Number of subjects: 28
Study 16583215 — intervention group
Group type: EXPERIMENTAL
Intervention: T2* measurements
Number of subjects: 28
Study 14747688 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 2970
Study 14747688 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 2970
Study 11232003 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat meal (LF; 20% fat, 68% carbohydrate, 12% protein)
Number of subjects: 11
Study 11232003 — intervention group
Group type: COMPARATOR
Intervention: High fat meal (HF; 48% fat, 40% carbohydrate, 12% protein)
Number of subjects: 11
Study 11232003 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat meal (LF)
Number of subjects: 11
Study 11232003 — intervention group
Group type: COMPARATOR
Intervention: High fat meal (HF)
Number of subjects: 11
Study 9262538 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 240
Study 9262538 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 240
Study 8517102 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (3.75 vol‐% in 70% nitrous oxide in oxygen)
Number of subjects: 36
Study 8517102 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 36
Study 3629090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg arecoline
Number of subjects: 18
Study 3629090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3629090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg glycopyrrolate
Number of subjects: 18
Study 3629090 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 18
Study 29324401 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release carbamazepine monotherapy (CBZ-CR)
Number of subjects: 207
Study 29324401 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine and valproate combination therapy (LTG+VPA)
Number of subjects: 207
Study 26924671 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise and muscle-strengthening exercises, 20 weeks, 3-5 sessions per week of 90 minutes each.
Number of subjects: 100
Study 26924671 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 100
Study 24511907 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-mediated social support (CMSS) groups
Number of subjects: 111
Study 21254378 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial lumbar puncture on day 8 in remission induction therapy
Number of subjects: 754
Study 21254378 — intervention group
Group type: COMPARATOR
Intervention: Initial lumbar puncture on day 1 (previous studies)
Number of subjects: 754
Study 21254378 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall event-free survival at 4 years
Number of subjects: 754
Study 21254378 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-year cumulative incidence of any CNS relapse
Number of subjects: 754
Study 20354750 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenous monthly for 6 months)
Number of subjects: 40
Study 20354750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18048433 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (60 mg/day for 1 week)
Number of subjects: 8
Study 18048433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16523204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar beet pectin (SBP)
Number of subjects: 66
Study 16523204 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX)
Number of subjects: 66
Study 16523204 — intervention group
Group type: COMPARATOR
Intervention: Control (no fiber enrichment)
Number of subjects: 66
Study 14586912 — intervention group
Group type: EXPERIMENTAL
Intervention: BWS group (body-weight support)
Number of subjects: 100
Study 14586912 — intervention group
Group type: COMPARATOR
Intervention: no-BWS group (full weight bearing)
Number of subjects: 100
Study 10764307 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-S1
Number of subjects: 1258
Study 10764307 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-S2
Number of subjects: 1258
Study 8923024 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (beta-carotene, vitamin C, and vitamin E) for three years
Number of subjects: 2200
Study 8923024 — intervention group
Group type: COMPARATOR
Intervention: Placebo for three years
Number of subjects: 2200
Study 1356479 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 200 mg
Number of subjects: 15
Study 1356479 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 15
Study 31486188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 11096
Study 29778606 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag 60 mg
Number of subjects: 435
Study 29778606 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag 40 mg
Number of subjects: 435
Study 29778606 — intervention group
Group type: COMPARATOR
Intervention: Avatrombopag
Number of subjects: 435
Study 27922020 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg every other day (EOD), once a morning (OM)
Number of subjects: 88
Study 27922020 — intervention group
Group type: COMPARATOR
Intervention: Standard antihypertensive pharmacotherapy
Number of subjects: 88
Study 23807278 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 ml of 0.5 % bupivacaine plus 150 mg magnesium sulphate (in 3 ml 0.9 % saline)
Number of subjects: 50
Study 23248063 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate renal denervation
Number of subjects: 47
Study 23248063 — intervention group
Group type: COMPARATOR
Intervention: Crossover to renal denervation after 6 months
Number of subjects: 47
Study 20211816 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride
Number of subjects: 0
Study 20211816 — intervention group
Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 0
Study 18332043 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 5187
Study 18332043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5187
Study 15707414 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 200
Study 15707414 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CyA)
Number of subjects: 200
Study 15707414 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and preemptive withdrawal of immunosuppression
Number of subjects: 200
Study 15707414 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of immunosuppression
Number of subjects: 200
Study 11861346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter (PAC) use in patients with severe ventricular impairment and unstable angina
Number of subjects: 345
Study 11861346 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC use in patients with ventricular impairment alone
Number of subjects: 345
Study 11861346 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC use in patients with unstable angina alone
Number of subjects: 345
Study 11861346 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC use in routine patients without complicating risk factors
Number of subjects: 345
Study 11861346 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC use frequency and practice volume
Number of subjects: 345
Study 11861346 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing medical education participation
Number of subjects: 345
Study 10414567 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency neurotomy
Number of subjects: 28
Study 10414567 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat radiofrequency neurotomy
Number of subjects: 28
Study 7677296 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine
Number of subjects: 246
Study 7677296 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine
Number of subjects: 246
Study 2123183 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + glibenclamide
Number of subjects: 26
Study 2123183 — intervention group
Group type: COMPARATOR
Intervention: Insulin + placebo
Number of subjects: 26
Study 6972513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (12.5 mg/kg, two doses on the first day of life)
Number of subjects: 44
Study 6972513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 30802635 — intervention group
Group type: EXPERIMENTAL
Intervention: Fan + exercise advice
Number of subjects: 40
Study 30802635 — intervention group
Group type: EXPERIMENTAL
Intervention: Calming Hand + exercise advice
Number of subjects: 40
Study 30802635 — intervention group
Group type: EXPERIMENTAL
Intervention: Fan + Calming Hand + exercise advice
Number of subjects: 40
Study 30802635 — intervention group
Group type: COMPARATOR
Intervention: Exercise advice alone
Number of subjects: 40
Study 29093180 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (IV or SC) at doses of 1, 4, or 7 mg/kg
Number of subjects: 49
Study 29093180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 29093180 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (IV)
Number of subjects: 49
Study 29093180 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (highest-dose IV group)
Number of subjects: 49
Study 25870986 — intervention group
Group type: EXPERIMENTAL
Intervention: ART12 (12 weeks of antiretroviral therapy)
Number of subjects: 200
Study 25870986 — intervention group
Group type: EXPERIMENTAL
Intervention: ART48 (48 weeks of antiretroviral therapy)
Number of subjects: 200
Study 25870986 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no ART)
Number of subjects: 200
Study 25870986 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping ART
Number of subjects: 200
Study 23823106 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 0 cm H2O
Number of subjects: 30
Study 23823106 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 6 cm H2O
Number of subjects: 30
Study 23823106 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 12 cm H2O
Number of subjects: 30
Study 23823106 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (various levels)
Number of subjects: 30
Study 23823106 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP and positioning
Number of subjects: 30
Study 21793420 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaques-Dalcroze eurhythmics
Number of subjects: 0
Study 20086319 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI)
Number of subjects: 28
Study 20086319 — intervention group
Group type: COMPARATOR
Intervention: Skimmed curd protein (SMP)
Number of subjects: 28
Study 17275199 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 218
Study 17275199 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 218